Breast Cancer | Specialty

Dr. Carey on Treating Triple-Negative Breast Cancer

February 28th 2015

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Early Intervention Essential for Proper Lymphedema Management

February 27th 2015

Moving early to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming more severe.

Driver Mutations Remain Prognostic But Not Predictive in Breast Cancer

February 27th 2015

Tumor genome profiling identifies driver mutations in breast tumors, however, it is still too early to use this information in clinical decision making.

Neoadjuvant Endocrine Therapy Appropriate in Select Patients

February 27th 2015

While not appropriate for all patients with ER-positive breast cancer, neoadjuvant endocrine therapy could play an important role in select groups of women with comorbidities or those with ER-rich/luminal A disease.

Excitement Building for PARP Inhibitors in BRCA-Mutated Breast Cancer

February 27th 2015

The FDA's recent approval of the first PARP inhibitor suggests that this new class of targeted therapy has great potential to help not only patients with ovarian cancer for whom the agent is indicated but also individuals with breast cancer.

Dr. Tripathy on the Possibility of Curing Metastatic Breast Cancer

February 26th 2015

Debu Tripathy, MD, professor of medicine, chair, department of breast medical oncology, The University of Texas MD Anderson Cancer Center, discusses the possibility of one day being able to cure metastatic breast cancer.

Dr. Attai on What Physicians Can Learn from Social Media

February 26th 2015

Deanna J. Attai, MD, breast surgeon, assistant clinical professor of surgery, David Geffen School of Medicine, University of California, Los Angeles, explains how social media can help physicians.

MBCC Embraces Revolution in Breast Cancer Care

February 26th 2015

The landscape of breast cancer care is shifting rapidly, but that doesn't worry the organizers of the 32nd Annual Miami Breast Cancer Conference.

Three Experts Examine the ER-Positive Treatment Landscape

February 26th 2015

With the evolution of treatment under way, OncLive interviewed three world-renowned experts in the field: Joanne L. Blum, MD, PhD, Adam M. Brufsky, MD, PhD, and Harold J. Burstein, MD, PhD.

Future Treatments for Triple-Negative Breast Cancer

February 25th 2015

Chemotherapeutics for Triple-Negative Breast Cancer

February 25th 2015

Standard Therapies for Triple-Negative Breast Cancer

February 25th 2015

Managing Brain Metastases in Breast Cancer

February 25th 2015

Role of T-DM1 in HER2-Positive Breast Cancer

February 25th 2015

Pertuzumab in HER2-Positive Metastatic Breast Cancer

February 25th 2015

BOLERO-2: Everolimus Plus Exemestane in Resistant MBC

February 25th 2015

Role of Bevacizumab in Breast Cancer

February 25th 2015

Endocrine Therapy Resistance in Breast Cancer

February 25th 2015

CDK4/6 Inhibition in Metastatic Breast Cancer

February 25th 2015

Treating ER-Positive De Novo Metastatic Breast Cancer

February 25th 2015